In a 41-year-old woman with type 2 diabetes, weight 110 kg, taking olanzapine (Zyprexa) 5 mg twice daily and furosemide (Lasix) 40 mg daily, with a current insulin‑to‑carbohydrate ratio of 1 unit per 12 g carbs, insulin sensitivity factor of 50 mg/dL per unit, and blood glucose readings of 364 mg/dL at 11:00 after a 69‑g carbohydrate meal and 409 mg/dL at 17:00, what should her insulin sensitivity factor, insulin‑to‑carbohydrate ratio, and basal insulin (Lantus, insulin glargine) dose be?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 6, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Insulin Adjustment Recommendations

This patient requires immediate and aggressive insulin dose adjustments: increase the Lantus basal dose to approximately 22 units daily (0.2 units/kg), tighten the ICR to 1:10, and strengthen the ISF to 1:40, with close monitoring over the next 3-5 days given the significant hyperglycemia and olanzapine-induced insulin resistance.

Critical Context: Olanzapine's Impact

This patient is on olanzapine 5 mg BID (10 mg total daily), which is a major contributor to her poor glycemic control. Olanzapine is among the most diabetogenic atypical antipsychotics, causing severe insulin resistance and hyperglycemia through multiple mechanisms 1, 2. The drug interactions are explicit: atypical antipsychotics like olanzapine decrease the blood glucose-lowering effect of insulin, requiring dosage increases and more frequent monitoring 1.

Analysis of Current Insulin Regimen Failure

Your patient's glucose data reveals profound insulin inadequacy:

  • Morning BG 364 mg/dL after eating 69g carbs
  • Afternoon BG 409 mg/dL (6 hours later, suggesting both bolus and basal failure)
  • Current ICR of 1:12 would have given ~5.75 units for 69g carbs
  • Current ISF of 1:50 would add ~4.3 units correction (from 364)
  • Total bolus ~10 units failed to prevent BG rising to 409

This represents both:

  1. Inadequate basal insulin (allowing baseline drift upward)
  2. Insufficient bolus coverage (ICR and ISF both too weak)

Basal Insulin (Lantus) Adjustment

Starting Dose Calculation

For type 2 diabetes patients not previously on insulin, guidelines recommend 10 units or 0.2 units/kg daily 3, 4. At 110 kg:

  • 0.2 units/kg = 22 units daily

Initiate Lantus at 22 units once daily (same time each day). This is appropriate given her weight and the severity of hyperglycemia (both readings >300 mg/dL) 3, 4.

Titration Protocol

Use an evidence-based algorithm, increasing 2 units every 3 days until fasting plasma glucose reaches 80-130 mg/dL 3. More aggressive titration (4 units every 3 days) is justified when FPG remains >180 mg/dL 5, 6.

Target fasting glucose: 100-130 mg/dL initially (can tighten to 80-110 mg/dL once stable).

Monitoring for Overbasalization

Watch for clinical signals suggesting basal doses are excessive (typically >0.5-1.0 units/kg or ~55-110 units in this patient) without achieving targets 7, 5. If basal exceeds these thresholds without glycemic improvement, consider adding GLP-1 RA rather than further basal escalation 3.

Insulin-to-Carbohydrate Ratio (ICR) Adjustment

Current ICR of 1:12 is clearly inadequate. The patient consumed 69g carbs, received ~5.75 units, yet glucose rose from 364 to 409 mg/dL.

Tighten ICR to 1:10 (1 unit per 10g carbs):

  • This represents a 20% increase in bolus insulin
  • For 69g carbs: would give 6.9 units (vs. current 5.75 units)
  • Type 2 diabetes patients are typically more insulin resistant, often requiring ratios of 1:8 to 1:12 7

Further Titration

If postprandial glucose remains >180 mg/dL 2 hours after meals with 1:10 ratio, tighten further to 1:8 after 3-5 days of observation.

Insulin Sensitivity Factor (ISF) Adjustment

Current ISF of 1:50 is too weak. The correction dose of ~4.3 units (for BG 364) failed to prevent further rise to 409 mg/dL.

Strengthen ISF to 1:40 (1 unit lowers glucose by 40 mg/dL):

  • This represents a 25% increase in correction doses
  • For BG 364 with target 120: (364-120)/40 = 6.1 units correction
  • Combined with meal bolus: more aggressive glucose reduction

Rule of Thumb

A common starting ISF calculation is 1800 ÷ total daily insulin dose. Once basal is optimized (estimated 40-50 units total daily insulin with basal + bolus), ISF would be approximately 1800/45 = 1:40, confirming this recommendation 5.

Critical Medication Interaction Management

Furosemide 40 mg daily can also impair glucose tolerance, though less significantly than olanzapine 1. Monitor for:

  • Volume depletion (can concentrate glucose)
  • Electrolyte abnormalities affecting insulin secretion

Immediate Action Plan

  1. Tonight: Start Lantus 22 units at bedtime (or same time daily)
  2. Tomorrow: Implement ICR 1:10 and ISF 1:40 for all meals
  3. Days 1-3: Monitor fasting and pre-meal glucose 4 times daily
  4. Day 4: Increase Lantus by 2-4 units if fasting glucose >130 mg/dL
  5. Days 4-7: Continue monitoring, adjust ICR/ISF if postprandial targets not met
  6. Week 2: Reassess total regimen, expect basal needs of 30-40 units

Hypoglycemia Precautions

With more aggressive dosing, prescribe glucagon for emergency hypoglycemia 3. Educate on recognition and treatment of hypoglycemia. If BG <70 mg/dL occurs, reduce the corresponding insulin dose by 10-20% 3, 4.

Long-term Considerations

  • Consider GLP-1 RA addition (e.g., semaglutide) to reduce insulin requirements and promote weight loss, particularly important given olanzapine-induced weight gain 3, 7
  • Discuss olanzapine alternatives with prescribing psychiatrist if glycemic control remains poor despite optimized insulin
  • Target total daily insulin: 0.5-1.0 units/kg (55-110 units) may be needed given severe insulin resistance 7, 5

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.